EWING, N.J., Jul 22, 2014 (BUSINESS WIRE) -- Antares Pharma, Inc. today announced that the first patient has been dosed in a double-blind, multiple-dose, phase 3 study to evaluate the efficacy and safety of QuickShot® Testosterone (QS T) administered subcutaneously once each week to...